Home » Stocks » XNCR

Xencor, Inc. (XNCR)

Stock Price: $36.94 USD -0.10 (-0.27%)
Updated Jun 18, 2021 4:00 PM EDT - Market closed
After-hours: $33.30 -3.65 (-9.87%) Jun 18, 4:49 PM
Market Cap 2.15B
Revenue (ttm) 124.27M
Net Income (ttm) -63.75M
Shares Out 58.00M
EPS (ttm) -1.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 18
Last Price $36.94
Previous Close $37.04
Change ($) -0.10
Change (%) -0.27%
Day's Open 36.57
Day's Range 36.12 - 37.24
Day's Volume 413,804
52-Week Range 29.28 - 58.34

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoi...

3 weeks ago - Business Wire

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoi...

3 weeks ago - Business Wire

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...

Other stocks mentioned: BMY
3 weeks ago - Business Wire

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...

1 month ago - Business Wire

Xencor (XNCR) delivered earnings and revenue surprises of 94.81% and 160.31%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...

1 month ago - Business Wire

On Wednesday, May 05, Xencor (NASDAQ:XNCR) will release its latest earnings report. Check out Benzinga's preview to understand the implications.

1 month ago - Benzinga

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoi...

1 month ago - Business Wire

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoi...

1 month ago - Business Wire

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...

2 months ago - Business Wire

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoi...

3 months ago - Business Wire

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...

3 months ago - Business Wire

Xencor Inc (NASDAQ: XNCR) and UCLA Technology Development Group have agreed to develop novel therapeutic antibodies utilizing Xencor's modular suite of XmAb technology platforms.  Xencor's XmAb platform...

3 months ago - Benzinga

MONROVIA, Calif. & LOS ANGELES--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of can...

3 months ago - Business Wire

Xencor (XNCR) delivered earnings and revenue surprises of 55.56% and 97.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...

3 months ago - Business Wire

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...

4 months ago - Business Wire

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...

4 months ago - Business Wire

Xencor (XNCR) signs a strategic research collaboration deal with MD Anderson Cancer Center to develop and commercialize T Cell-engaging bispecific antibodies for treating cancer.

5 months ago - Zacks Investment Research

MONROVIA, Calif. & HOUSTON--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune...

5 months ago - Business Wire

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases,...

6 months ago - Business Wire

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, ...

6 months ago - Business Wire

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases,...

7 months ago - Business Wire

MONROVIA, Calif. & PLANEGG/MUNICH, Germany & WILMINGTON, Del.--(BUSINESS WIRE)--Xencor (NASDAQ: XNCR), MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and Incyte (NASDAQ: INC...

Other stocks mentioned: INCY, MOR
7 months ago - Business Wire

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases,...

7 months ago - Business Wire

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases,...

7 months ago - Business Wire

Xencor Inc (XNCR) CEO Bassil Dahiyat on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Xencor (XNCR) delivered earnings and revenue surprises of 0.00% and -2.45%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases,...

7 months ago - Business Wire

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, ...

7 months ago - Business Wire

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease,...

7 months ago - Business Wire

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases,...

8 months ago - Business Wire

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases,...

8 months ago - Business Wire

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc.

9 months ago - Business Wire

MONROVIA, Calif. & HOUSTON--(BUSINESS WIRE)--Xencor, Inc.

9 months ago - Business Wire

The second half of 2020 is well underway, and with markets recovering, one of the strongest industries leading the charge has been biotech.

Other stocks mentioned: DVAX, IBB, IMGN, LXRX, VKTX
10 months ago - 24/7 Wall Street

Xencor Inc (XNCR) CEO Bassil Dahiyat on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Xencor (XNCR) delivered earnings and revenue surprises of -8.93% and 43.47%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc.

10 months ago - Business Wire

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc.

10 months ago - Business Wire

Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10 months ago - Zacks Investment Research

These hidden gems have the potential to deliver significant returns to their shareholders over the long run.

Other stocks mentioned: SPPI
11 months ago - The Motley Fool

MONROVIA, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of ...

11 months ago - Business Wire

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases...

11 months ago - Business Wire

Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q4 2019 - Earnings Call Transcript

1 year ago - Seeking Alpha

Xencor (XNCR) delivered earnings and revenue surprises of 9.62% and -47.76%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

About XNCR

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases in the United states and internationally. The company's product candidates include Obexelimab, an immune inhibitor that has completed Phase 2 clinical trial for the treatment of IgG4-related disease and systemic lupus erythematosus, as well as in Phase 1b/2a clinical trial to treat moderate-to-severe rheumatoid arthritis; Plamotamab, a... [Read more...]

Industry
Biotechnology
IPO Date
Dec 3, 2013
CEO
Bassil Dahiyat
Employees
202
Stock Exchange
NASDAQ
Ticker Symbol
XNCR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for Xencor stock is "Buy." The 12-month stock price forecast is 54.00, which is an increase of 46.18% from the latest price.

Price Target
$54.00
(46.18% upside)
Analyst Consensus: Buy